Our newest board members are officially introduced!
On the 24th of May in 2017, the general assembly meeting took place and fatefully decided Oslo Cancer Cluster’s newest board members. These members, despite having some big seats to fill, will take on a respectful duty belonging to the board: where professionals in the field function as the governing body for the company.
Oslo Cancer Cluster wished to see their new board members possess backgrounds from both the University of Oslo and Oslo’s University Hospital, where experience in innovation and clinical expertise follow. They also wished for a pharmaceutical representative with international involvement. Seeing the results, it seems like the wish came true.
Innovation and Clinical Expertise
Inger Sandlie is one of the new members . She is a professor at the Department of Biosciences, University of Oslo, and research group leader at the Department of Immunology, Oslo University Hospital. She is also deputy director of the Centre for Immune Regulation. The centre identifies and investigates novel mechanisms of immune dysregulation to advance the development of therapeutics.
Sandlie has co-authored more than 120 publications, supervised 15 PhDs, received awards for scientific innovation and is co-founder of Nextera A/S and Vaccibody A/S. She presently consults for Syntimmune A/S (Boston, US) as well as Albumedix A/S (Nottingham, UK), and serves on the board of the technology transfer office of the University of Oslo (Inven2) and The Norwegian Radium Hospital Research Foundation.
When asked why, in short, she has become a board member, Sandlie responded:
– I work within a network of scientists and biotechnology companies, and thus I think it’s extremely important to use this network alongside Oslo Cancer Cluster in order to influence positive change, as well as using its potential the best way possible.
Our other newest board member, Professor Øyvind Bruland, has a two decades experience as consultant oncologist at Radiumhospitalet, Oslo University Hospital. His main and tenure position is as professor of clinical oncology, University of Oslo. He specializes in primary bone and soft tissue cancers as well as skeletal metastases brought on by prostate and breast cancer. He has co-authored approximately 200 publications and supervised more than 20 PhD candidates. Bruland is one of the founders of the successful Norwegian biotech companies Algeta and Nordic Nanovector. He is also a co-founder of Oncoinvent.
When asked the same question as Sandlie, Bruland responded:
– I’m impressed with what Oslo Cancer Cluster has accomplished, but I think within certain areas like commercialization, some “new thinking” and support is needed. It’s important that we don’t get lost in bureaucracy.
Our third and final new board member, Benedikte Thunes Akre, has experience as a medical director at AstraZeneca, a global science-led pharmaceutical business with great success. On top of this, Thunes Akre has a long line of experience working with oncology throughout her career. Her response to why she has become a board member, was as follows:
– My main interest and experience throughout my career has been focused on oncology. The field is constantly emerging and I would like to contribute ensuring that Norwegian expertise is seen and recognized nationally as well as internationally, with the ultimate goal of improving the lives of patients.
Future and Past
In addition to the three new board members, Oslo Cancer Cluster is happy to include a new honourable member of the board: Jónas Einarsson. During the last 16 years, he has acted as the CEO for The Radium Hospital Hospital Research Foundation. He is also the founder and former CEO and chairman of the board of Oslo Cancer Cluster and Oslo Cancer Cluster Innovation Park.
The future looks promising with our newest board members. We thank our previous board members, Ingvild Hagen, Professor Svein Stølen, and Professor Gunnar Seter for their great time, effort and contribution!